Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Venetoclax API

Product
  • Therapeutic Category 抗がん/腫瘍

  • CAS Number

    1257044-40-8

  • API Technology

    High Potent

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF

Mechanism of Action

Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.

Indication

VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

アビラテロン酢酸エステル

抗がん/腫瘍

arrow

ニロチニブ塩酸塩

抗がん/腫瘍

arrow

ロムスチン

抗がん/腫瘍

arrow

アザシチジン

抗がん/腫瘍

arrow

ベンダムスチン塩酸塩

抗がん/腫瘍

arrow

ボルテゾミブ

抗がん/腫瘍

arrow

カバジタキセル

抗がん/腫瘍

arrow

カボザンチニブS-リンゴ酸塩

抗がん/腫瘍

arrow

カペシタビン

抗がん/腫瘍

arrow

カルフィルゾミブ

抗がん/腫瘍

arrow

デシタビン

抗がん/腫瘍

arrow

デュクラバシチニブ

抗がん/腫瘍

arrow

ゲムシタビン

抗がん/腫瘍

arrow

オラパリブ( A型)

抗がん/腫瘍

arrow

パゾパニブ

抗がん/腫瘍

arrow

ポマリドミド

抗がん/腫瘍

arrow

レルゴリクス

抗がん/腫瘍

arrow

リプレチニブ

抗がん/腫瘍

arrow

ダロルタミド

抗がん/腫瘍

arrow

フルキンチニブ

抗がん/腫瘍

arrow

ザヌブルチニブ

抗がん/腫瘍

arrow

ゾレドロン酸

抗がん/腫瘍

arrow

ベネトクラクス

抗がん/腫瘍

arrow

ツカチニブ

抗がん/腫瘍

arrow

カボザンチニブ塩酸塩

抗がん/腫瘍

arrow

ダサチニブ一水和物

抗がん/腫瘍

arrow

エンザルタミド(結晶およびプレミックス)

抗がん/腫瘍

arrow

エリブリンメシル酸塩

抗がん/腫瘍

arrow

レナリドミド( A型)

抗がん/腫瘍

arrow

ペメトレキセド二ナトリウム七水和物

抗がん/腫瘍

arrow

グラニセトロン

抗がん/腫瘍

arrow

ミドスタウリン(非晶質お よびII型)

抗がん/腫瘍

arrow

アパルタミド(非晶質およ びB型)

抗がん/腫瘍

arrow

レンバチニブメシ ル酸塩(C型およびMIBK溶媒和物)

抗がん/腫瘍

arrow

ニラパリブトシル酸塩

抗がん/腫瘍

arrow

アダグラシブ

抗がん/腫瘍

arrow

ピルトブルチニブ

抗がん/腫瘍

arrow

パルボシクリブ(A型)

抗がん/腫瘍

arrow

アカラブルチニブ

arrow

FAQs

What are the uses of Venetoclax API?
  • Treats chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML)

How do you store Venetoclax API?
  • Store in original container at or below 30°C (86°F), protect from moisture

What are the precautions to take while using Venetoclax API?
  • Avoid live vaccines
    Monitor for tumor lysis syndrome (TLS)
    Ensure adequate hydration

What is the dosage form and strength currently available for Venetoclax?
  • Available as oral tablets: 10 mg, 50 mg, 100 mg

免責事項

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.